Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

Vito Longo, Oronzo Brunetti, Antonio Gnoni, Stefano Cascinu, Giampietro Gasparini, Vito Lorusso, Domenico Ribatti, Nicola Silvestris

Research output: Contribution to journalReview articlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early loco-regional spread and distant metastases at diagnosis, leading to dismal prognosis with a 5-year overall survival rate moderately over than 5%. This malignancy is largely resistant to chemotherapy and radiation, but the reasons of the refractoriness to the therapies is still unknown. Evidence is accumulating to indicate that the PDAC microenvironment and vascularity strongly contribute to the clinical features of this disease. In particular, PDAC is characterized by excessive dense extracellular matrix deposition associated to vasculature collapse and hypoxia with low drug delivery, explaining at least partly the low efficacy of antiangiogenic drugs in this cancer. Strategies aimed to modulate tumor stroma favoring vasculature perfusion and chemotherapeutics delivery are under investigation.

Original languageEnglish
Pages (from-to)58649-58658
Number of pages10
Issue number36
Publication statusPublished - 2016


  • Angiogenesis
  • Desmoplastic reaction
  • Hypoxia
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue'. Together they form a unique fingerprint.

Cite this